16.29
-0.47(-2.80%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
111
First IPO Date
March 20, 2014
| Name | Title | Pay | Year Born |
| Mr. Ofer Gonen B.Sc. | Chief Executive Officer | 850,000 | 1973 |
| Mr. Yaron Meyer Adv. | Executive Vice President, General Counsel & Corporate Secretary | 318,000 | 1979 |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research & Development Officer | 384,000 | 1962 |
| Ms. Hani Luxenburg | Chief Financial Officer | 395,000 | 1973 |
| Dr. Shmulik Hess Ph.D. | Chief Operating Officer & Chief Commercial Officer | 430,000 | 1973 |
| Dr. Lior Rosenberg M.D. | Co-Founder | 727,000 | 1946 |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer | 0 | 1950 |
| Dr. Liron Gal | Executive Director of Manufacturing Science & Technology | 0 | N/A |
| Mr. Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | 0 | 1967 |
| Ms. Hagit Mashiach | Vice President of Human Resources | 0 | N/A |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.